Chemistry:Emestedastat
Emestedastat (proposed brand name Xanamem; developmental code name UE-2343) is a steroidogenesis inhibitor which is under development for the treatment of major depressive disorder, Alzheimer's disease, and fragile X syndrome.[1][2] It specifically acts as a centrally penetrant inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and thereby inhibits the synthesis of the glucocorticoid steroid hormone cortisol.[1][3][4][2] As of August 2024, emestedastat is in phase 2 clinical trials for major depressive disorder and Alzheimer's disease and is in the preclinical stage of development for fragile X syndrome.[1][2] Clinical effectiveness for Alzheimer's disease has been mixed.[2] It was originated by the University of Edinburgh and is being developed by Actinogen Medical.[1]
References
- ↑ 1.0 1.1 1.2 1.3 "UE 2343". 28 August 2024. https://adisinsight.springer.com/drugs/800042157.
- ↑ 2.0 2.1 2.2 2.3 "11β-Hydroxysteroid dehydrogenase and the brain: Not (yet) lost in translation". Journal of Internal Medicine 295 (1): 20–37. January 2024. doi:10.1111/joim.13741. PMID 37941106.
- ↑ "Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention". Pharmacological Research 129: 216–226. March 2018. doi:10.1016/j.phrs.2017.11.021. PMID 29170097.
- ↑ "Is AD a Stress-Related Disorder? Focus on the HPA Axis and Its Promising Therapeutic Targets". Frontiers in Aging Neuroscience 11. 2019. doi:10.3389/fnagi.2019.00269. PMID 31611783.
 |  |
